Pfizer

Отворен

СекторЗдравеопазване

27.79 0.04

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.57

Максимум

27.94

Ключови измерители

By Trading Economics

Приходи

-2.9B

-238M

Продажби

583M

15B

P/E

Средно за сектора

37.434

56.597

EPS

0.77

Дивидентна доходност

5.97

Марж на печалбата

-1.583

Служители

75,000

EBITDA

-3.8B

1.2B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+2.41% upside

Дивиденти

By Acuity

Дивидентна доходност

Средно за сектора

5.97%

2.18%

Следващи печалби

3.11.2026 г.

Следваща дата на екс-дивидент

6.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

19B

162B

Предишно отваряне

27.75

Предишно затваряне

27.79

Настроения в новините

By Acuity

48%

52%

127 / 339 Класиране в Healthcare

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.09.2026 г., 20:08 ч. UTC

News
Social Media

Pfizer shares are lower as the company announces a webcast featuring CEO Albert Bourla at the Morgan Stanley Healthcare Conference scheduled for September 2026.

4.09.2026 г., 23:05 ч. UTC

Pfizer Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid mixed economic signals affecting market sentiment.

3.09.2026 г., 23:01 ч. UTC

Pfizer Inc. shares are lower in after-market hours, following a weak trading session and amid broader market softness from recent economic data on jobless claims.

2.09.2026 г., 23:06 ч. UTC

Pfizer Inc. shares are lower in after-market hours, amid a weaker ADP payrolls report signaling potential labor market weakness affecting future Federal Reserve policy.

1.09.2026 г., 20:09 ч. UTC

News

Pfizer Inc shares reached a 22-month high of $28.86 today, driven by a significant upward trend in the Pharmaceuticals sub-sector amid overall market gains.

31.08.2026 г., 23:06 ч. UTC

Pfizer Inc shares rose in after-hours trading, holding above the 20-day moving average and near the upper end of their one-month range.

28.08.2026 г., 23:01 ч. UTC

Pfizer Inc. shares are lower in after-market trading, continuing a trend from the previous three sessions. No specific news was identified to explain the decline.

27.08.2026 г., 23:02 ч. UTC

Social Media
News

Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine, COMIRNATY XFG, boosting shares in after-market trading.

26.08.2026 г., 23:06 ч. UTC

Pfizer Inc shares are lower in after-market hours amid notable volatility. Broader market weakness and a stronger U.S. Dollar Index contributed to the decline.

25.08.2026 г., 23:06 ч. UTC

Pfizer Inc. shares are lower in after-market trading, reflecting weaker sentiment amid broader market declines linked to falling crude oil prices.

24.08.2026 г., 19:36 ч. UTC

Pfizer Inc. shares are lower today, continuing a decline since Friday's close. The stock remains above its 20-day moving average.

21.08.2026 г., 23:01 ч. UTC

Pfizer Inc shares are lower in after-market trading, reflecting a downward trend amid broader market volatility related to inflation and government debt concerns.

20.08.2026 г., 19:41 ч. UTC

Pfizer Inc's shares are lower today amid a broader downturn in the Pharmaceuticals sub-sector, marking a shift from recent gains.

19.08.2026 г., 23:51 ч. UTC

Pfizer Inc shares are lower in after-market hours, reversing gains from three consecutive sessions. No specific news was identified to explain the price action.

18.08.2026 г., 19:16 ч. UTC

Social Media
Event

Pfizer reported second-quarter adjusted EPS of $0.77, exceeding estimates, and raised its sales outlook for fiscal year 2026, with shares trading higher.

17.08.2026 г., 23:36 ч. UTC

Event

Pfizer Inc shares are lower in after-market hours following the announcement of Xtandi's new indication for prostate cancer treatment. The broader market also declined.

14.08.2026 г., 23:51 ч. UTC

Pfizer Inc. shares are higher in after-market hours amid broader economic concerns following a reported decline in U.S. retail sales for July.

13.08.2026 г., 23:16 ч. UTC

Pfizer Inc shares are lower in after-market hours following a decline from earlier gains. No specific news was identified to explain the movement.

12.08.2026 г., 23:02 ч. UTC

Social Media
News

Pfizer shares rose after Chairman Albert Bourla bought 38,000 shares at $26.34, totaling about $1 million, signaling confidence in the company's prospects.

11.08.2026 г., 19:26 ч. UTC

News

Pfizer Inc. shares are lower amid a $44 million settlement over its Chantix drug, which allegedly contained a cancer-linked substance.

10.08.2026 г., 23:01 ч. UTC

Pfizer Inc. shares are lower in after-market hours, continuing a decline since Monday's close amid rising Treasury yields and inflation concerns.

8.08.2026 г., 00:02 ч. UTC

Pfizer Inc shares are lower in after-market hours with no specific news identified. Broader market concerns about interest rate hikes continue to influence sentiment.

7.08.2026 г., 23:01 ч. UTC

Pfizer Inc shares are lower in after-market hours, reaching a session low earlier. No specific news was identified to explain the decline.

6.08.2026 г., 23:51 ч. UTC

Pfizer Inc shares are lower in after-market hours. The decline follows increased crude oil prices and a strengthening U.S. dollar, contributing to market volatility.

5.08.2026 г., 23:02 ч. UTC

Pfizer Inc shares are modestly higher in after-market hours, reaching a session high before pulling back slightly. No specific news was identified for the movement.

4.08.2026 г., 23:21 ч. UTC

Pfizer Inc shares are lower in after-market hours, with no specific news identified for the decline. Broader market sentiment remains positive amid falling crude oil prices.

3.08.2026 г., 23:46 ч. UTC

Social Media

Pfizer Inc shares are higher in after-market trading ahead of earnings. The stock remains above its 20-day moving average, reflecting positive market sentiment.

31.07.2026 г., 23:06 ч. UTC

Pfizer Inc shares are higher in after-market hours, reflecting slight gains since Friday's close. The stock remains near the upper end of its one-month range.

30.07.2026 г., 23:26 ч. UTC

Event

Pfizer shares are higher in after-market trading following Phase 3 trial results for LITFULO in nonsegmental vitiligo, despite three prior sessions of lower closes.

29.07.2026 г., 23:16 ч. UTC

News

Pfizer and BioNTech received European Commission approval for their XFG-adapted COVID-19 vaccine, valid across all EU member states. Shares are trading roughly flat after-market.

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

2.41% нагоре

12-месечна прогноза

Среден 28.46 USD  2.41%

Висок 35.75 USD

Нисък 25 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

21 ratings

7

Купи

13

Задържане

1

Продай

Настроение

By Acuity

127 / 339 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat